Bio Plus Co

Bio Plus Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 15.01 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 25.13 B KRW — a change of -40.30% (lower).

EBITDA

15.01 BKRW

YoY

-40.30%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bio Plus Co is 2025 15.01 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bio Plus Co was 2024 25.13 B KRW. It decreases by -40.30% lower compared to the previous year.

The Bio Plus Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
3.97 B KRW
Jan 1, 2019
7.26 B KRW
Jan 1, 2020
12.50 B KRW
Jan 1, 2021
17.01 B KRW
Jan 1, 2022
26.01 B KRW
Jan 1, 2023
29.01 B KRW
Jan 1, 2024
25.13 B KRW
Jan 1, 2025
15.01 B KRW
The Bio Plus Co EBITDA history
YEAREBITDAYoY
15.01 BKRW-40.30%
25.13 BKRW-13.37%
29.01 BKRW+11.54%
26.01 BKRW+52.91%
17.01 BKRW+36.10%
12.50 BKRW+72.25%
7.26 BKRW+82.60%
3.97 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bio Plus Co is 15.01 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bio Plus Co changed from 25.13 B KRW to 15.01 B KRW, representing a -40.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bio Plus Co

All Key Metrics — Bio Plus Co